Kaiser Permanente
Division of Research Spotlight
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. We seek to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 550-plus staff is working on more than 350 epidemiological and health services research projects.
In part 2 of our profile series, meet the last three of the seven early-career researchers who began their post-doctoral appointments this past year and represent not only diverse communities but diverse research interests as well.
Seven early-career researchers began their post-doctoral appointments this past year and represent not only diverse communities but diverse research interests as well. This is Part 1 of our new class profile.
With December 1 marking World AIDS Day, this infectious disease expert looks at the state of HIV/AIDS research. And despite his Northern California location, admits he's a diehard Los Angeles Lakers fan.
Kaiser Permanente Division of Research scientists recently presented research on influenza vaccines, colorectal screening outcomes in HIV-infected individuals, a genetic basis for fever after measles-containing vaccines, and more at ID Week, a leading conference on infectious diseases.
Dr. Klein’s latest research raised some interesting questions about when influenza vaccinations are most effective, so we spoke with her to learn more and answer some common flu vaccine questions.
Kaiser Permanente study confirms recommendations for catch-up HPV vaccination with 3 doses in females aged 15 to 20, but not when started at or after age 21.
A new study shows that a treatment regimen of 8 weeks for hepatitis C may be just as effective as 12 weeks in black patients. The study also showed that more people overall can take advantage of the shorter treatment durations, which has important implications for access given the medication’s high cost.
